BioCentury

7:00 AM GMT, Jun 26, 2006
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Innate's TLR3 land grab

Innate Pharma S.A. says last week's deals with Schering-Plough Corp. and the Institut de Cancerologie Gustave Roussy give the company an opportunity to develop products in the toll-like receptor space, exploiting compounds where the mechanism of action already has been demonstrated. Two days after announcing the deals, the company proposed to go public on Euronext Paris(see "IPO Watch: Europe," A16).

Read the full 607 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.